Curing "incurable" cancer

Cancer Discovery

Volumn 1, Issue 6, 2011, Pages 477-480

  Watson, James D ^a  

^a Cold Spring Harbor Laboratory ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ERLOTINIB; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; METFORMIN; PROTEIN P53; SMAD4 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL DIVISION; CELL GROWTH; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; NEOPLASM; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84866684351     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0220     Document Type: Article

References (20)

1. Clarkson B, Baserga R, editors. Control of proliferation in animal cells. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1974.
2. Feramisco J, Ozanne B, Stiles C, editors. Cancer cells: growth factors and transformation. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1985.
3. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
4. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell 2003;3:347-61.
5. Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science 1994;263:98-101.
6. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer. Eur J Cancer 2010;46:1260-70.
7. Lasfar A and Cohen-Solal KA. Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place? Carcinogenesis 2010;31:1710-7.
8. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-7.
9. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-73.
10. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-40.
11. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008;13:7-9.
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
13. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009;325:1555-9.
14. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G, et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011;25:460-70.
15. Shackelford DB and Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009;9:563-75.
16. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.
17. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52.
18. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011 Aug 3. [Epub ahead of print].
19. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
20. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008;455:679-83.